Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania

Life Sciences

Volumn 79, Issue 3, 2006, Pages 281-286

  Frey, Benício N ^a,b   Andreazza, Ana C ^a,b   Ceresér, Keila M M ^b   Martins, Márcio R ^c   Valvassori, Samira S ^c   Réus, Gislaine Z ^c   Quevedo, João ^c   Kapczinski, Flávio ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Amphetamine; Bipolar disorder; Brain derived neurotrophic factor; Lithium; Mania; Valproate

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DEXAMPHETAMINE; LITHIUM; MOOD STABILIZER; SODIUM CHLORIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; LOCOMOTION; MAINTENANCE THERAPY; MALE; MANIA; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; RAT;

AFFECT; AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LITHIUM; MALE; RATS; RATS, WISTAR; VALPROIC ACID;

ANIMALIA;

EID: 33646866337     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.01.002     Document Type: Article

References (41)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth ed. (1994), American Psychiatric Association, Washington, D.C.
2. Anand A., Verhoeff P., Seneca N., Zoghbi S.S., Seibyl J.P., Charney D.S., and Innis R.B. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. American Journal of Psychiatry 157 7 (2000) 1108-1114
3. Aylmer C.G., Steinberg H., and Webster R.A. Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?. Psychopharmacology (Berl) 91 2 (1987) 198-206
4. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., and Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of Sciences of the United States of America 101 14 (2004) 5099-5104
5. Bebchuk J.M., Arfken C.L., Dolan-Manji S., Murphy J., Hasanat K., and Manji H.K. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Archives of General Psychiatry 57 1 (2000) 95-97
6. Bell E.C., Willson M.C., Wilman A.H., Dave S., Asghar S.J., and Silverstone P.H. Lithium and valproate attenuate dextroamphetamine-induced changes in brain activation. Human Psychopharmacology 20 2 (2005) 87-96
7. Belmaker R.H. Bipolar disorder. The New England Journal of Medicine 351 5 (2004) 476-486
8. Bertolino A., Frye M., Callicott J.H., Mattay V.S., Rakow R., Shelton-Repella J., Post R., and Weinberger D.R. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biological Psychiatry 53 10 (2003) 906-913
9. Bezchlibnyk Y., and Young L.T. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Canadian Journal of Psychiatry 47 2 (2002) 135-148
10. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., Kanai H., Hough C., Hiroi T., and Leeds P. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disorders 4 2 (2002) 129-136
11. Coyle J.T., and Duman R.S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38 2 (2003) 157-160
12. Deicken R.F., Pegues M.P., Anzalone S., Feiwell R., and Soher B. Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. American Journal of Psychiatry 160 5 (2003) 873-882
13. Duman R.S. Synaptic plasticity and mood disorders. Molecular Psychiatry 7 (2002) S29-S34 (Suppl)
14. Einat H., Kofman O., and Belmaker R.H. Animal models of bipolar disorder: from a single episode to progressive cycling models. In: Myslobodsky M., and Weiner I. (Eds). Contemporary Issues in Modeling Psychopathology (2000), Kluwer Academic Publishers, Boston 165-180
15. Einat H., Yuan P., Gould T.D., Li J., Du J., Manji H.K., and Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood regulation. Journal of Neuroscience 23 19 (2003) 7311-7316
16. Ellenbroek B.A., and Cools A.R. Animal models with construct validity for schizophrenia. Behavioural Pharmacology 1 6 (1990) 469-490
17. Frey, B.N., Martins, M.R., Petronilho, F.C., Dal-Pizzol, F., Quevedo, J., Kapczinski, F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as an animal model of acute mania. Bipolar Disorders (in press).
18. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., and Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158 1 (2001) 100-106
19. Gould T.D., and Manji H.K. The Wnt signaling pathway in bipolar disorder. Neuroscientist 8 5 (2002) 497-511
20. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., and Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization. Nature 411 6833 (2001) 86-89
21. Hashimoto R., Takei N., Shimazu K., Christ L., Lu B., and Chuang D.M. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43 7 (2002) 1173-1179
22. Hashimoto K., Shimizu E., and Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research Reviews 45 (2004) 104-114
23. Joyce P.R., Fergusson D.M., Woollard G., Abbott R.M., Horwood L.J., and Upton J. Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. Journal of Affective Disorders 33 4 (1995) 233-243
24. Kupfer D.J. The increasing medical burden in bipolar disorder. Journal of American Medical Association 293 20 (2005) 2528-2530
25. Lamberty Y., Margineanu D.G., and Klitgaard H. Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy and Behavior 2 5 (2001) 454-459
26. Li X., Ketter T.A., and Frye M.A. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?. Journal of Affective Disorders 69 1-3 (2002) 1-14
27. Machado-Vieira R., Kapczinski F., and Soares J.C. Perspectives for the development of animal models of bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28 2 (2004) 209-224
28. Mai L., Jope R.S., and Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. Journal of Neurochemistry 82 1 (2002) 75-83
29. Manji H.K., and Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Molecular Psychiatry 7 Suppl 1 (2002) S46-S56
30. Manji H.K., and Lenox R.H. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biological Psychiatry 48 6 (2000) 518-530
31. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nature Medicine 7 5 (2001) 541-547
32. Narita M., Aoki K., Takagi M., Yajima Y., and Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119 3 (2003) 767-775
33. Okada K., Oishi R., and Saeki K. Inhibition by antimanic drugs of hyperactivity induced by methamphetamine-chlordiazepoxide mixture in mice. Pharmacology, Biochemistry and Behavior 35 4 (1990) 897-901
34. Pandey G.N., Dwivedi Y., SridharaRao J., Ren X., Janicak P.G., and Sharma R. Protein kinase C and phospholipase C activity and expression of their specific isozymes is decreased and expression of MARCKS is increased in platelets of bipolar but not in unipolar patients. Neuropsychopharmacology 26 2 (2002) 216-228
35. Pantazopoulos H., Stone D., Walsh J., and Benes F.M. Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 54 3 (2004) 147-155
36. Smith D.F. Central and peripheral effects of lithium on amphetamine-induced hyperactivity in rats. Pharmacology, Biochemistry and Behavior 14 4 (1981) 439-442
37. Soares J.C., Chen G., Dippold C.S., Wells K.F., Frank E., Kupfer D.J., Manji H.K., and Mallinger A.G. Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Research 95 2 (2000) 109-118
38. Strakowski S.M., and Sax K.W. Progressive behavioral response to repeated d-amphetamine challenge: further evidence for sensitization in humans. Biological Psychiatry 44 11 (1998) 1171-1177
39. Vogel M., Pfeifer S., Schaub R.T., Grabe H.J., Barnow S., Freyberger H.J., and Cascorbi I. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50 4 (2004) 305-310
40. Wang H.Y., and Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biological Psychiatry 40 7 (1996) 568-575
41. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S., MacQueen G., McIntyre R., Sharma V., Silverstone P., Alda M., Baruch P., Beaulieu S., Daigneault A., Milev R., Young L.T., Ravindran A., Schaffer A., Connoly M., and Gorman C.P. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders 7 Suppl 3 (2005) 5-69